Physician profile
Ian Foxall
NPI 1528008109
$11,060.99
in general payments reported to CMS, 2019-2025
57 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $1,229 · 2021: $1,525 · 2022: $1,998 · 2023: $2,197 · 2024: $1,768 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,121.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,835.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,329.53 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,261.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,034.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $648.39 | 2019-2025 | |
| Amgen INC. | $551.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $361.07 | 2019-2024 | Freestyle Libre, Freestyle Libre 3, Proclaim |
| Kowa Pharmaceuticals America, INC. | $332.59 | 2019-2022 | |
| Amarin Pharma, INC. | $311.80 | 2019-2023 | |
| Glaxosmithkline, LLC. | $295.14 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $262.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.72 | 2019-2024 | Belsomra, Steglatro, Dificid |
| Novartis Pharmaceuticals Corporation | $196.52 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.28 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $183.33 | 2023-2025 | Cologuard Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Foxall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.